title: End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
abstract: We report some end results with GnRH agonist (GnRHa) treatment in central precocious puberty (CPP), in terms of final height (FH), ovarian function, peak bone mass, body composition and psychological problems. The two studies reported (Study I and II) are part of the activity of the Italian Study Group for Physiopathology of Puberty. Study L Growth data were analyzed of three groups of patients: treated with i.n. spray buserelin, i.m. triptorelin and untreated. Both GnRHa administration modes were effective in arresting pubertal development and all girls had complete recovery of the reproductive axis after therapy. Treated patients showed an improvement in final height in comparison with untreated patients and compared to predicted height at the start of treatment with both agonist treatments. However, patients treated with the long-acting slow release preparation had a better improvement in adult height and reached or exceeded the genetic height potential. Study II. In a retrospective evaluation of the outcome in 71 girls with idiopathic CPP treated with triptorelin, we found that FH fell within the population norm and the target range in 87.3% and 90% of the patients respectively. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a bone age of 12.0-12.5 yr. Finally, we and other groups have recently found normal values of bone mineral density in girls at the end of GnRHa treatment in the great majority of patients.
authors.affiliation: Pediatric Clinic, University of Verona, Italy. francoa@borgoroma.univr.it
authors.forename: F
authors.initials: F
authors.lastname: Antoniazzi
authors.forename: T
authors.initials: T
authors.lastname: Arrigo
authors.forename: M
authors.initials: M
authors.lastname: Cisternino
authors.forename: F
authors.initials: F
authors.lastname: Galluzzi
authors.forename: S
authors.initials: S
authors.lastname: Bertelloni
authors.forename: A M
authors.initials: AM
authors.lastname: Pasquino
authors.forename: P
authors.initials: P
authors.lastname: Borrelli
authors.forename: D
authors.initials: D
authors.lastname: Osio
authors.forename: F
authors.initials: F
authors.lastname: Mengarda
authors.forename: F
authors.initials: F
authors.lastname: De Luca
authors.forename: L
authors.initials: L
authors.lastname: Tatò
mesh_terms: D000336:Aerosols; D001827:Body Height / Q000187:drug effects; D015519:Bone Density; D001846:Bone Development; D001927:Brain Diseases / Q000150:complications*; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003692:Delayed-Action Preparations; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D007273:Injections, Intramuscular; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin